Exemestane (Aromasin)

Overview

Exemestane, sold as Aromasin, is an aromatase inhibitor — it prevents the conversion of testosterone to estradiol. Medically it is approved for breast cancer therapy in postmenopausal women; use in the context described here is off-label throughout and at considerably lower doses.

It differs from the more common anastrozole in one structural respect that has practical consequences: exemestane binds the aromatase enzyme irreversibly.

Mechanism of Action

The aromatase enzyme converts androgens to estrogens. Anastrozole and letrozole block it reversibly — they occupy the enzyme temporarily, and when the substance clears, the enzyme resumes work. That is the mechanism behind the rebound effect: after stopping, estradiol can overshoot because production restarts while the accumulated substrate is still present.

Exemestane works differently. It is structurally similar to the enzyme's natural substrate, binds to it and permanently inactivates it. New aromatase has to be produced before conversion resumes. This is why there is no rebound after stopping, and why the effect lasts considerably longer than the twenty-four-hour half-life suggests.

A second difference concerns the lipid profile. The non-steroidal inhibitors tend to worsen it; exemestane, being a steroidal compound with weak androgenic activity of its own, does not — and in some data slightly improves it. In a context where the substances being used already put pressure on HDL, that matters.

Typical Context

Exemestane is used when estradiol is measurably elevated during a cycle and symptoms match — water retention, sensitive nipples, mood swings. The important qualifier is measurably.

The most common mistake with aromatase inhibitors of any kind is preventive use. Not every cycle produces problematic estradiol, and estrogen is not something to be eliminated: it is needed for lipid metabolism, bone density, libido, joint comfort and mood. Driving it too low produces symptoms that look confusingly similar to too much — joint pain, low libido, flat mood. Anyone answering those with a higher dose makes the problem worse.

Because the enzyme block is irreversible, doses can be lower and intervals longer than intuition suggests. Six and a quarter to twelve and a half milligrams every few days is often sufficient.

There is a second and more fundamental error worth naming: using an aromatase inhibitor with compounds that do not aromatize. Trenbolone, the DHT derivatives and oxymetholone either produce no estradiol at all or act directly at the receptor. An inhibitor there does not address the mechanism causing the symptoms — it only lowers an estradiol that was already insufficient.

Side Effects & Risks

• Estradiol driven too low, with joint pain, loss of libido and flat mood
• Fatigue
• Effects on bone density with prolonged use
• Headache
• Nausea, particularly at the higher approved doses
• Unlike non-steroidal inhibitors: no relevant worsening of the lipid profile

Blood Work & Monitoring

• Estradiol (sensitive) — the deciding value; measure before and during, never dose blind
• Total/free testosterone — for context
• Lipid profile (LDL, HDL, triglycerides) — as a baseline
• Liver values (ALT, AST, GGT)

Harm-Reduction Notes

• Measure estradiol before starting; do not use preventively
• The target is the normal range, not the lowest possible value
• Joint pain and low libido usually mean estradiol is too low, not too high
• Start with low doses; the irreversible block means less is needed than expected
• Not the right tool for non-aromatizing compounds
• No rebound after stopping, unlike anastrozole — which makes it the more forgiving choice
• Keep the duration limited; long-term estrogen suppression affects bone density